840 related articles for article (PubMed ID: 27873319)
21. Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer.
Zhou H; Hu Y; Luo R; Zhao Y; Pan H; Ji L; Zhou T; Zhang L; Long H; Fu J; Wen Z; Wang S; Wang X; Lin P; Yang H; Wang J; Song M; Yi X; Yang L; Xia X; Guan Y; Fang W; Yang Y; Hong S; Huang Y; Li P; Zhang Y; Zhou N
Nat Commun; 2021 Sep; 12(1):5431. PubMed ID: 34521849
[TBL] [Abstract][Full Text] [Related]
22. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.
Walch AK; Zitzelsberger HF; Aubele MM; Mattis AE; Bauchinger M; Candidus S; Präuer HW; Werner M; Höfler H
Am J Pathol; 1998 Oct; 153(4):1089-98. PubMed ID: 9777940
[TBL] [Abstract][Full Text] [Related]
23. Next-generation sequencing of salivary high-grade neuroendocrine carcinomas identifies alterations in RB1 and the mTOR pathway.
Goyal B; Duncavage EJ; Martinez D; Lewis JS; Chernock RD
Exp Mol Pathol; 2014 Dec; 97(3):572-8. PubMed ID: 25446844
[TBL] [Abstract][Full Text] [Related]
24. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
25. Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors.
D'Adda T; Bottarelli L; Azzoni C; Pizzi S; Bongiovanni M; Papotti M; Pelosi G; Maisonneuve P; Antonetti T; Rindi G; Bordi C
Mod Pathol; 2005 Jun; 18(6):795-805. PubMed ID: 15578070
[TBL] [Abstract][Full Text] [Related]
26. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
27. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.
Voortman J; Lee JH; Killian JK; Suuriniemi M; Wang Y; Lucchi M; Smith WI; Meltzer P; Wang Y; Giaccone G
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13040-5. PubMed ID: 20615970
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of mixed pulmonary carcinoma and carcinoid: the driver from their mono-clonal origin.
Graziano P; Parente P; Centra F; Milione M; Centonze G; Volante M; Cavazza A; Urbano D; Di Maggio G; Balsamo T; Di Micco C; Rossi G; Rossi A; Muscarella LA
Virchows Arch; 2024 Jan; 484(1):37-46. PubMed ID: 37773451
[TBL] [Abstract][Full Text] [Related]
29. Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis.
Sampietro G; Tomasic G; Collini P; Biganzoli E; Boracchi P; Bidoli P; Pilotti S
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):49-56. PubMed ID: 10937049
[TBL] [Abstract][Full Text] [Related]
30. Genetic characterisation of sarcomatoid carcinomas reveals multiple novel actionable mutations and identifies
Ding Y; Shao Y; Na C; Yin JC; Hua H; Tao R; Jiang Y; Hu R; He X; Miao C; Zhu D; Zhang Z
J Med Genet; 2022 Jan; 59(1):10-17. PubMed ID: 33115932
[TBL] [Abstract][Full Text] [Related]
31. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
[TBL] [Abstract][Full Text] [Related]
32. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Augert A; Zhang Q; Bates B; Cui M; Wang X; Wildey G; Dowlati A; MacPherson D
J Thorac Oncol; 2017 Apr; 12(4):704-713. PubMed ID: 28007623
[TBL] [Abstract][Full Text] [Related]
33. Clinic and genetic similarity assessments of atypical carcinoid, neuroendocrine neoplasm with atypical carcinoid morphology and elevated mitotic count and large cell neuroendocrine carcinoma.
Zhang Y; Wang W; Hu Q; Liang Z; Zhou P; Tang Y; Jiang L
BMC Cancer; 2022 Mar; 22(1):321. PubMed ID: 35331190
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
Ohmoto A; Sato Y; Asaka R; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takeuchi K; Mori S; Takahashi S
Mod Pathol; 2021 Nov; 34(11):1979-1989. PubMed ID: 34247193
[TBL] [Abstract][Full Text] [Related]
35. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
Shamir ER; Devine WP; Pekmezci M; Umetsu SE; Krings G; Federman S; Cho SJ; Saunders TA; Jen KY; Bergsland E; Jones K; Kim GE; Kakar S; Chiu CY; Joseph NM
Mod Pathol; 2019 Feb; 32(2):290-305. PubMed ID: 30237525
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H
Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611
[TBL] [Abstract][Full Text] [Related]
37. Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.
Pelosi G; Bianchi F; Dama E; Simbolo M; Mafficini A; Sonzogni A; Pilotto S; Harari S; Papotti M; Volante M; Fontanini G; Mastracci L; Albini A; Bria E; Calabrese F; Scarpa A
Virchows Arch; 2018 Apr; 472(4):567-577. PubMed ID: 29388013
[TBL] [Abstract][Full Text] [Related]
38. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
[TBL] [Abstract][Full Text] [Related]
39. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract][Full Text] [Related]
40. Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.
Boora GK; Kanwar R; Kulkarni AA; Pleticha J; Ames M; Schroth G; Beutler AS; Banck MS
Cancer Genet; 2015; 208(7-8):374-81. PubMed ID: 26087898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
